ArticleArthritis care & research2026
Treatment Sequencing and Line of Therapy for Biologics and JAK Inhibitors in Patients With Rheumatoid Arthritis: Implications for Design and Uptake of New Drugs and Predictive Biomarker Diagnostics.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveThe opportunity for new biomarker-based tests to predict treatment response and the appropriate use of emerging rheumatoid arthritis (RA) therapies may depend on patients' treatment history. We examined RA treatment sequences and biologic/JAK inhibitor (JAKi) initiation overall and by line of therapy (LoT) to estimate the size of the eligible RA patient population in the United States for a new predictive treatment response test using a population-based RA inception cohort.
methodsWe used an augmented health plan claims database to create an inception cohort of patients with RA and estimated the rate of advanced treatment (biologic or JAKi) addition or switch. Results were stratified by advanced treatment-naïve versus treatment-experienced status and also described specific RA treatment sequences and combinations over time.
resultsAmong 37,656 patients with RA, 59,557 new RA treatment initiations were identified. Most patients (85.2%) initiated biologics; the remainder initiated JAKi. Of these, 40.2% used biologics/JAKi as monotherapy. The overall biologic/JAKi addition/switch rate was 25.7 per 100 patient-years (py) (22.7/100 py in biologic-naïve patients and >30/100 py in treatment-experienced patients). Rates varied substantially between prescribers, with an observed add/switch rate in the practices of prescribers in the highest decile (53.8/100 py) more than four-fold greater than rates in the practice of prescribers in the lowest decile (12.1/100 py).
conclusionThese findings highlight the size and characteristics of the eligible RA population in the United States initiating a new RA biologic or JAKi treatment each year, thus providing valuable insights for stakeholders developing or marketing new RA therapies or biomarker-based diagnostic tests to predict future treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.